NASDAQ: MPLTMaplight Therapeutics Inc Stock
$14.03-0.99 (-6.59%)
Updated Jul 30, 2026
MPLT Price
$14.03
Fair Value Price
$0.93
Market Cap
$636.20M
52 Week Low
$9.10
52 Week High
$40.43
P/E
N/A
P/B
1.59x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
N/A
Beta
1.08
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
MPLT Overview
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MPLT's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -12.86% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MPLT
Ranked#413 of 462
Ranked#413 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $258.38 | A | |
| $11.06 | A | |
| $8.42 | A |
Be the first to know about important MPLT news, forecast changes, insider trades & much more!
MPLT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MPLT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MPLT ($14.03) is overvalued by 1,409.17% relative to our estimate of its Fair Value price of $0.93 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MPLT ($14.03) is not significantly undervalued (1,409.17%) relative to our estimate of its Fair Value price of $0.93 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MPLT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more MPLT due diligence checks available for Premium users.
Valuation
MPLT fair value
Fair Value of MPLT stock based on Discounted Cash Flow (DCF)
Price
$14.03
Fair Value
$0.93
Overvalued by
1,409.17%
MPLT ($14.03) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MPLT ($14.03) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MPLT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
20.57x
Market
17.04x
MPLT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.59x
Industry
5.4x
MPLT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MPLT's financial health
Profit margin
Revenue
$0.0
Net Income
-$60.7M
Profit Margin
0%
Assets to liabilities
Assets
$418.8M
Liabilities
$19.0M
Debt to equity
0.05
MPLT's short-term assets ($327.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MPLT's short-term assets ($327.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MPLT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$51.2M
Investing
$67.0M
Financing
-$6.9M
MPLT vs Biotech Stocks
Maplight Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.